Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Clene Nanomedicine | 2026 | Post-IPO Equity | Undisclosed | Salt Lake City |
| Whitehawk Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Pacific Palisades |
| Provivi | 2026 | Debt Financing | Undisclosed | Santa Monica |
| Bonum Therapeutics | 2026 | Venture - Series Unknown | Undisclosed | Seattle |
| Trevi Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Sandy Hook |
| Revolution Medicines | 2026 | Post-IPO Equity | Undisclosed | Redwood City |
| Ossium Health | 2026 | Venture - Series Unknown | Undisclosed | San Francisco |
| Zenas BioPharma | 2026 | Post Ipo Equity | $100.0M | Waltham |
| SAB Biotherapeutics | 2026 | Post Ipo Equity | $85.0M | Sioux Falls |
| Alto Neuroscience | 2026 | Post Ipo Equity | $120.0M | Los Altos |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Clene Nanomedicine | Post-IPO Equity | Undisclosed | Salt Lake City, United States |
| 2 | Whitehawk Therapeutics | Post-IPO Equity | Undisclosed | Pacific Palisades, United States |
| 3 | Provivi | Debt Financing | Undisclosed | Santa Monica, United States |
| 4 | Bonum Therapeutics | Venture - Series Unknown | Undisclosed | Seattle, United States |
| 5 | Trevi Therapeutics | Post-IPO Equity | Undisclosed | Sandy Hook, United States |
| 6 | Revolution Medicines | Post-IPO Equity | Undisclosed | Redwood City, United States |
| 7 | Ossium Health | Venture - Series Unknown | Undisclosed | San Francisco, United States |
| 8 | Zenas BioPharma | Post Ipo Equity | $100.0M | Waltham, United States |
| 9 | SAB Biotherapeutics | Post Ipo Equity | $85.0M | Sioux Falls, United States |
| 10 | Alto Neuroscience | Post Ipo Equity | $120.0M | Los Altos, United States |
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.
Provivi develops biopesticides for agriculture, commercial, household, and public health pest management.
Bonum Therapeutics creates a technology platform to treat a wide range of diseases.
Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Ossium Health builds a bone marrow bank to treat blood cancers.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Positrigo is a company dedicated to the development, production, and sales of dedicated brain positron emission tomography (PET) scanners.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Neocis develops robot-assisted dental implant surgery with the aim of transforming dental surgery using advanced robotics.
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Tebra provide independent healthcare practices with digital tools and support to thrive in a new era of healthcare.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.
Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Vivo Capital has invested in 105 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Vivo Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 21 different industry categories.
Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. Vivo Capital's total known invested capital is $5.6B.
Vivo Capital's average investment size is $78.6M across its portfolio of 105 companies.
Recent Vivo Capital portfolio additions include Clene Nanomedicine, Whitehawk Therapeutics, Provivi, Bonum Therapeutics, Trevi Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors